News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
386,918 Results
Type
Article (22881)
Company Profile (144)
Press Release (363871)
Multimedia
Podcasts (126)
Webinars (20)
Section
Business (113478)
Career Advice (1016)
Deals (19832)
Drug Delivery (124)
Drug Development (55087)
Employer Resources (80)
FDA (8843)
Job Trends (8441)
News (200713)
Policy (18849)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (907)
Accelerated approval (35)
Adcomms (25)
Allergies (128)
Alliances (29486)
ALS (145)
Alzheimer's disease (1058)
Antibody-drug conjugate (ADC) (367)
Approvals (9257)
Artificial intelligence (506)
Autoimmune disease (234)
Automation (34)
Bankruptcy (188)
Best Places to Work (6202)
BIOSECURE Act (14)
Biosimilars (227)
Biotechnology (63)
Bladder cancer (161)
Brain cancer (52)
Breast cancer (521)
Cancer (4167)
Cardiovascular disease (361)
Career advice (859)
Career pathing (30)
CAR-T (180)
CDC (22)
Cell therapy (500)
Cervical cancer (34)
Clinical research (49825)
Collaboration (1642)
Company closure (3)
Compensation (792)
Complete response letters (70)
COVID-19 (1374)
CRISPR (80)
C-suite (886)
Cystic fibrosis (111)
Data (5737)
Decentralized trials (3)
Denatured (29)
Depression (118)
Dermatology (66)
Diabetes (378)
Diagnostics (2559)
Digital health (34)
Diversity (10)
Diversity, equity & inclusion (22)
Drug discovery (265)
Drug pricing (220)
Drug shortages (36)
Duchenne muscular dystrophy (208)
Earnings (47795)
Editorial (53)
Employer branding (10)
Employer resources (79)
Events (58382)
Executive appointments (854)
FDA (11470)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (8)
Frontotemporal dementia (20)
Funding (1172)
Gene editing (164)
Generative AI (48)
Gene therapy (437)
GLP-1 (952)
Government (2336)
Grass and pollen (8)
Guidances (283)
Healthcare (7052)
HIV (64)
Huntington's disease (34)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (81)
Immunology and inflammation (234)
Immuno-oncology (73)
Indications (155)
Infectious disease (1599)
Inflammatory bowel disease (164)
Inflation Reduction Act (13)
Influenza (72)
Intellectual property (194)
Interviews (140)
IPO (8280)
IRA (54)
Job creations (2495)
Job search strategy (751)
JPM (56)
Kidney cancer (14)
Labor market (74)
Layoffs (366)
Leadership (35)
Legal (4367)
Liver cancer (59)
Longevity (17)
Lung cancer (598)
Lymphoma (327)
Machine learning (36)
Management (31)
Manufacturing (799)
MASH (140)
Medical device (3077)
Medtech (3125)
Mergers & acquisitions (12378)
Metabolic disorders (1200)
mRNA (121)
Multiple sclerosis (144)
NASH (21)
Neurodegenerative disease (288)
Neuropsychiatric disorders (98)
Neuroscience (2190)
Neurotech (1)
NextGen: Class of 2026 (2613)
Non-profit (1194)
Now hiring (60)
Obesity (654)
Opinion (252)
Ovarian cancer (142)
Pain (201)
Pancreatic cancer (199)
Parkinson's disease (266)
Partnered (19)
Patents (402)
Patient recruitment (472)
Peanut (36)
People (36859)
Pharmaceutical (72)
Pharmacy benefit managers (36)
Phase 1 (15591)
Phase 2 (21141)
Phase 3 (16940)
Pipeline (6542)
Policy (259)
Postmarket research (1729)
Preclinical (5696)
Press Release (35)
Prostate cancer (230)
Psychedelics (36)
Radiopharmaceuticals (230)
Rare diseases (837)
Real estate (3333)
Recruiting (34)
Regulatory (15897)
Reports (29)
Research institute (1006)
Resumes & cover letters (160)
Rett syndrome (38)
RNA editing (18)
RSV (65)
Schizophrenia (169)
Series A (205)
Series B (151)
Service/supplier (8)
Sickle cell disease (91)
Special edition (24)
Spinal muscular atrophy (132)
Sponsored (24)
Startups (2149)
State (2)
Stomach cancer (14)
Supply chain (105)
Tariffs (98)
The Weekly (94)
Vaccines (562)
Venture capital (92)
Weight loss (455)
Women's health (82)
Worklife (10)
Date
Last 7 days (479)
Last 30 days (2251)
Last 365 days (20365)
2026 (8781)
2025 (20939)
2024 (21114)
2023 (21967)
2022 (28675)
2021 (29448)
2020 (27567)
2019 (22051)
2018 (17083)
2017 (18667)
2016 (17474)
2015 (20188)
2014 (15759)
2013 (13231)
2012 (14167)
2011 (14524)
2010 (13351)
Location
Africa (475)
Alabama (55)
Alaska (1)
Arizona (121)
Arkansas (11)
Asia (28006)
Australia (3666)
California (8640)
Canada (2588)
China (1097)
Colorado (320)
Connecticut (413)
Delaware (359)
Europe (59426)
Florida (1244)
Georgia (173)
Hawaii (3)
Idaho (31)
Illinois (735)
India (78)
Indiana (377)
Iowa (12)
Japan (508)
Kansas (90)
Kentucky (38)
Louisiana (18)
Maine (7)
Maryland (898)
Massachusetts (6451)
Michigan (133)
Minnesota (364)
Mississippi (3)
Missouri (70)
Montana (13)
Nebraska (15)
Nevada (105)
New Hampshire (27)
New Jersey (2649)
New Mexico (23)
New York (2215)
North Carolina (1117)
North Dakota (5)
Northern California (4302)
Ohio (239)
Oklahoma (11)
Oregon (24)
Pennsylvania (1521)
Puerto Rico (26)
Rhode Island (31)
South America (696)
South Carolina (17)
South Dakota (1)
Southern California (3460)
Tennessee (101)
Texas (1279)
United States (30013)
Utah (147)
Virginia (291)
Washington D.C. (67)
Washington State (685)
West Virginia (3)
Wisconsin (116)
Wyoming (1)
386,918 Results for "sandoz pharma a g".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates
March 18, 2026
·
2 min read
C-suite
Lilly, J&J CEOs top pharma’s highest paid list—again
Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by more than $4 million.
May 13, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Sandoz Canada launches first ophthalmology biosimilar
February 2, 2026
·
3 min read
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma’s top paid CEOs make up to 358 times more than their employees; Revolution Medicine’s pancreatic cancer results highlight movement in the deadly disease space; more.
May 20, 2026
·
1 min read
·
Jef Akst
Patents
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
February 18, 2026
·
4 min read
·
Shawna Williams
Press Releases
Evotec Closes Sale of Just - Evotec Biologics’ Toulouse Site to Sandoz
December 8, 2025
·
5 min read
Government
RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media
The pharma industry “own Congress, they own the media,” Health Secretary Robert F. Kennedy, Jr. told lawmakers by way of explaining the bad press against FDA Commissioner Marty Makary following the second rejection of Replimune’s advanced melanoma drug.
April 17, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Outcome of Innate Pharma’s 2026 Annual General Meeting
May 22, 2026
·
2 min read
Earnings
On steadier ground, pharma heads into Q1 earnings with deals top of mind
During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral GLP-1 medicine, while other companies are expected to address the FDA, drug pricing and Trump’s new tariffs.
April 14, 2026
·
5 min read
·
Annalee Armstrong
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. in alignment with Trump’s Most Favored Nation policy, patients will suffer.
April 2, 2026
·
3 min read
·
Annalee Armstrong
1 of 38,692
Next
